Animal Model Market is Expected to Showcase Rampant Growth Over 2030

Growing Biopharmaceutical Research Will Positively Impact the Global Animal Model Market at a CAGR of 7.12% During the Forecast Period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Animal Model Market” that contains information from 2019 to 2035. The Animal Model Market is estimated to register a CAGR of 7.12% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Animal Model Market: Horizon Discovery Group plc, Charles River Laboratories International Inc., Transposagen Biopharmaceuticals Inc., Envigo, Taconic Biosciences, The Jackson Laboratory, GenOway, Eurofins Scientific, and Biocytogen.

Market Highlights

The Global Animal Model Market is projected to grow from USD 2.78 billion in 2024 to USD 5.92 billion by 2035, registering a CAGR of 7.12% during the forecast period.

The market growth is primarily driven by advancements in CRISPR and genetic engineering technologies, increasing biopharmaceutical R&D investments, and the rising use of animal models in vaccine, oncology, and neurological research. The COVID-19 pandemic further accelerated demand for animal models, particularly in preclinical testing of vaccines and antiviral drugs, underscoring their critical role in biomedical innovation.

Mice models dominate the market, accounting for nearly 95% of laboratory animals, owing to their genetic similarity to humans, rapid reproductive cycles, and cost-effectiveness. The pharmaceutical sector remains the largest end-user, utilizing animal models extensively for drug discovery, toxicity testing, and safety evaluations.

Recent industry developments — including Charles River Laboratories’ acquisition of Hera BioLabs (2025), Taconic Biosciences’ launch of a CRISPR-engineered rat model (2024), and The Jackson Laboratory’s NIH grant for rare disease research (2024) — reflect strong market momentum and continuous innovation in genetic model development.

Segment Analysis

The Global Animal Model Market has been segmented based on Animal Type, Technology, Application, and End User.

By Animal Type: The market is segmented into mice, rats, pigs, and others. The mice segment held the largest share in 2021 and will continue to dominate due to high reproducibility, genetic adaptability, and established use in preclinical studies.

By Technology: Segments include CRISPR, microinjection, and embryonic stem cell injection. The CRISPR segment leads the market and is expected to grow at the fastest rate, owing to its precision and efficiency in creating genetically modified models.

By Application: The research & development segment dominates due to its extensive use in drug screening, safety testing, and disease modeling.

By End User: The pharmaceutical companies segment accounted for the largest market share in 2021, driven by high demand for animal-based preclinical research and the surge in biologics and personalized medicine development.

Regional Analysis

By Region, the Animal Model Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

North America accounted for the largest share in 2021 and is expected to maintain its dominance due to strong pharmaceutical infrastructure, supportive regulatory frameworks, and increased vaccine research post-COVID-19.

Europe is the second-largest regional market, supported by the presence of numerous toxicology and immunology research centers in Germany, France, and the UK.

Asia-Pacific is expected to grow at the fastest CAGR through 2035, driven by expanding research facilities, growing government support for biotechnology, and increased R&D spending in countries like China, India, and Japan.

Key Findings of the Study

• The Global Animal Model Market is expected to reach USD 5.92 billion by 2035, at a CAGR of 7.12% during the forecast period.


• North America accounted for the largest market share, while Asia-Pacific is projected to be the fastest-growing regional market.


• CRISPR technology leads the innovation space, enhancing the precision of genetic modeling.


• Mice remain the most widely used laboratory animals, representing approximately 95% of total usage.


• Pharmaceutical companies dominate as the largest end-users, leveraging animal models for advanced preclinical testing and drug development.

Industry Developments

• Q2 2025: Charles River Laboratories acquires Hera BioLabs to expand its gene-edited animal model portfolio.


• Q1 2025: Envigo appoints a new CEO to drive global expansion and innovation in animal model services.


• Q2 2025: PerkinElmer launches a new zebrafish model platform for high-throughput drug screening.


• Q3 2024: Eurofins Scientific expands its animal model services through the acquisition of a preclinical CRO in Japan.


• Q1 2024: GenOway and Merck KGaA announce a partnership to co-develop next-generation humanized mouse models.

Future Outlook

• The Global Animal Model Market is set for substantial growth through 2035, fueled by rapid advancements in genetic modification, the rise of personalized medicine, and the globalization of biomedical research. Emerging opportunities lie in:


• Developing innovative animal models for rare and genetic diseases.


• Integrating AI and data analytics to enhance preclinical trial precision.


• Expanding academic-industry partnerships to promote collaborative research.


• By 2035, the market is expected to reflect strong innovation, ethical advancements, and strategic collaborations that will redefine the preclinical testing ecosystem.